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Plant extracts have a long history to be used in folk medicine. Cassia alata extracts are known to exert antibacterial activity but
details on compounds and mechanism of action remain poorly explored. We puriﬁed and concentrated the aqueous leaf extract
of C. alata by reverse phase-solid phase extraction and screened the resulting CaRP extract for antimicrobial activity. CaRP extract
exhibited antimicrobial activity for Pseudomonas aeruginosa, Staphylococcus epidermidis, S. aureus,a n dBacillus subtilis.C a R Pa l s o
inhibitedbioﬁlmformationofS.epidermidisandP. aeruginosa.Severalbacterialgrowth-inhibitingcompoundsweredetectedwhen
CaRP extract was fractionated by TLC chromatography coupled to bioautography agar overlay technique. HPLC chromatography
of CaRP extract yielded 20 subfractions that were tested by bioautography for antimicrobial activity against S. aureus and S.
epidermidis. Five bioactive fractions were detected and chemically characterized, using high-resolution mass spectrometry (qTOF-
MS/MS). Six compounds from four fractions could be characterized as kaempferol, kaempferol-O-diglucoside, kaempferol-O-
glucoside, quercetin-O-glucoside, rhein, and danthron. In the Salmonella/microsome assay CaRP showed weak mutagenicity
(MI < 3) only in strain TA98, pointing to a frameshift mutation activity. These results indicate that C. alata leaf extract contains
a minimum of 7 compounds with antimicrobial activity and that these together or as single substance are active in preventing
formation of bacterial bioﬁlm, indicating potential for therapeutic applications.
1.Introduction
CassiaalataL.(alsoknown as Sennaalata)is ashrub belong-
ing to the Fabaceae family, found in intertropical areas. It
is commonly known as candle bush, with reference to the
shapeofitsinﬂorescences.Itisannualorbiannualshrubwith
an oﬀensive smell, 1–4m tall, preferring sunny and moist
areas [1, 2]. Ethnopharmacological data available in a recent
review [1] describe various medical applications of C. alata
by populations from Africa (Uganda, Ghana, and Nigeria),
Indonesia, and Latin America (Guatemala, Martinique, and
Brazil).Leaves,ﬂowers,andfruitsofC.alataareusedasanti-
diabetic, anti-inﬂammatory, analgesic, against digestive pro-
blems, and infectious diseases (as antibacterial and antifun-
gal agents) [2–5]. Amongst the secondary metabolites are
steroids, ﬂavonoids, anthraquinones, anthrones, and a few
less common compounds such as ellagitannin, naphthalene,
phenolic acid, purine, and xanthone [1, 6–8]. Of special2 Evidence-Based Complementary and Alternative Medicine
interest are compounds such as kaempferol glycosides and
anthraquinones, already proven to have antimicrobial prop-
erties [1, 8].
The widespread use of C. alata in folk medicine [1]h a s
stimulated several scientiﬁc studies to search for its phar-
maceutically relevant compounds. Biological investigations
regarding anti-infection properties of C. alata extracts de-
monstrate action against Gram-positive bacilli (Bacillus sub-
tilis)a n dc o c c i( Enterococcus faecalis, Staphylococcus aureus,
and S. epidermidis)a sw e l la sG r a m - n e g a t i v eb a c i l l is u c ha s
Escherichia coli, Proteus vulgaris, and Pseudomonas aerugi-
nosa [9]. Extracts were also found to act against Aspergillus
niger, Candida albicans, Cryptococcus neoformans, and other
fungi [2, 3].
Nonetheless, the ability of C. alata extracts to prevent
bacterial adhesion and bioﬁlm formation remains poorly ex-
plored. In this respect, bioﬁlms are deﬁned as a consortium
ofmicroorganismsthatareattachedtoabioticorabioticsur-
face [10]. Compared with their planktonic counterparts, mi-
crobial cells living in bioﬁlms have extraordinary resistance
to the immune defense responses of the host as well as to
biocides and antimicrobial agents [11]. They have also been
shown to colonize a wide variety of medical devices and to
be associated with several human diseases [12], with S. epi-
dermidis and P. aeruginosa being the most prevalent patho-
gens involved in these infections [11, 12].
Solid-phase extraction (SPE) has been successfully used
to obtain root extract of C. alata prior to the use of High
Performance Liquid Chromatography (HPLC) [6]. However,
SPE has still not been applied to obtain C. alata leaf ex-
tracts with the main goal of trace substance enrichment,
matrix simpliﬁcation, and medium exchange in analytical
applicationssuchasinthebioautographyagaroverlay(BAO)
method [13, 14]. BAO is an alternative and more eﬃcient
version to the commonly used disc diﬀusion method in the
screening of natural compounds with antimicrobial poten-
tial as it allows direct activity testing after planar chromatog-
raphy of extracts [14]. The BAO method allows evaluation
of the compound via its diﬀusion from a Thin Layer Chro-
matography (TLC) plate into an overlay ﬁlm of agar medium
containing the microorganism to be tested for susceptibility.
This methodology has some advantages as it (i) can be used
for bioassay-guided isolation of compounds and (ii) simpli-
ﬁes the identiﬁcation and isolation of an active compound
from the crude extract [14].
In this study we therefore combined the SPE and BAO
methods to analyze the traditionally used decoction of C.
alata for compounds with antimicrobial activities, especially
those preventing bacterial growth and bioﬁlm formation.
Also, we investigated the extracts’ ability to interact with
DNA by performing genotoxicity assays with the crude ex-
tract to evaluate its safety using a prokaryotic model.
2.MaterialsandMethods
2.1. Microorganisms and Culture Conditions. Microorgan-
isms tested in this study were Staphylococcus aureus
(ATCC25921), Staphylococcus epidermidis (ATCC35984),
Pseudomonas aeruginosa (ATCC27853), Escherichia coli
(ATCC25923), Bacillus subtilis, Salmonella choleraesuis, Kleb-
siellapneumonia,Saccharomycescerevisiae,andCandidaalbi-
cans (CCMB286). Bacteria were obtained from the Ameri-
can Type Culture Collection (Manassas, USA) and clinical
isolates from volunteers of the Hospital Itabuna/BA-Brazil.
Salmonella typhimurium TA97a, TA98, TA100, TA102, and
TA1535 were kindly provided by B. M. Ames (University
of California, Berkeley, CA, USA). S. cerevisiae yeast strains
wereobtainedfromEUROSCARF(Frankfurt,Germany)and
C. albicans from the Colec ¸˜ ao de Culturas de Microrganismos
da Bahia, UEFS (Feira de Santana-BA, Brazil). All bacterial
strains were grown overnight at 37◦C in Mueller-Hinton
Broth (Merck) before tests and yeast strains were grown in
liquid YPD (yeast extract 1%, peptone 2% and dextrose 2%)
for 2-3 days at 30◦C in a rotatory shaker (New Brunswick,
G76) to attain stationary growth phase.
2.2. Solvents and Reagents. Acetonitrile (MeCN) HPLC-
grade was purchased from Tedia (USA). Water was puriﬁed
on a Milli-Q system (Millipore, USA). Ethanol (p.a.) was ob-
tained from Merck (Germany) while ethyl acetate (p.a.),
methanol (p.a.), and acetone (p.a.) was obtained from F.
Maia (Brazil). Streptomycin, chloramphenicol, ciproﬂoxa-
cin, and triﬂuoroacetic acid (TFA) for spectroscopy were
purchased from Sigma-Aldrich (USA). All culture media
were purchased from Merck (Germany) and Oxoid (Eng-
land).
2.3. Plant Material. Leaves of C. alata were collected at
Fazenda Ibaiti and at the campus of Universidade Estadual
de Santa Cruz, in Salobrinho, Ilh´ eus, BA, Brazil in August
2010. The lyophilized plant material was stored at room tem-
perature in desiccators in the dark. Voucher specimen were
deposited at UESC herbarium and identiﬁed by Professor
Luiz Alberto Mattos (curator) and also maintained at our
laboratory for future reference (Accession on August 12,
2010).
2.4. Extraction Procedure
2.4.1. Aqueous Extraction to Obtain CaAE. Aqueous extracts
(CaAE) were prepared by decoction using lyophilized leaves
[1:20; (w:v)] (80◦C, 30min) followed by ﬁltration, rotary
evaporation, and freeze-drying. One hundred grams of
milled leaves yielded 25.4 ± 2.9% (percentage extract of dry
weight) of crude aqueous extract. Lyophilized CaAE was
stored in a freezer at −20◦C until use.
2.4.2. Reverse Phase-Solid Phase Extraction to Obtain CaRP.
Cassia alata fraction (CaRP) was obtained using solid phase
extraction (SPE) methodology. SPE was performed using the
column Strata C18E 5g/20mL Giga Tubes (Phenomenex,
USA). One g of CaAE was diluted in 100mL of distilled
water. The cartridge was conditioned with acetone (25mL)
and washed with 5mL of water before loading the sample
(100mL). It was then washed with 20mL of water and
eluted with 25mL of ethyl acetate. After evaporation this
eluent yielded the CaRP fraction. One gram of CaAE yielded
6.4 ± 1.4% of CaRP that was stored in desiccators in theEvidence-Based Complementary and Alternative Medicine 3
darkatroomtemperatureuntilfurtheruse.Thevaluesrepre-
sent mean and standard deviation of at least 3 individual ex-
tractions.
2.5. Thin Layer Chromatography (TLC). One mg of each
sample was dissolved in either 2mL of water (CaAE) or
2mL of methanol (CaRP) and 40µL (ﬁnal concentration of
20µg/spot) was submitted to TLC on silica gel G60 F254 alu-
minumplates(Merck,10cm ×10cm).Eluentwasether/eth-
yl acetate/formic acid (75:25:1), according to Wagner and
Bladt [15]. Spots were detected by UV light at 254 and
365nm.
2.6. Bioautography Agar Overlay (BAO). Bioautography
using TLC plates plays an important role in the search for
active compounds from plants, giving quick access to infor-
mation concerning both the activity and the localization of
the activity in complex plant matrices. TLC chromatograms
were placed into sterile Petri dishes (20cm ∅) and sterilized
using UVC (254nm) light for 15min before being covered
by an overlay of bacterial growth media (40mL Mueller-
Hinton agar (Oxoid, England) containing 0.1% Triton-X) or
yeast media (YPD). After agar solidiﬁcation 400µLo fm i c r o -
bial suspension (2-3 × 108 cells/mL) was spread onto the
surface and then incubated for either 24h (bacteria) or 48h
(yeast).DuringthisgrowthperiodcompoundsfromtheTLC
plate could diﬀuse into agar and exert possible cytostatic
or cytotoxic action on the growing microorganisms. After
the incubation agar plates were sprayed with 2mg/mL (w/v)
aqueous solution of p-iodonitrotetrazolium (INT) (Sigma-
Aldrich, USA) and incubated for 2–6h. Microbial growth led
to the emergence of purple-red color resulting from the re-
duction of INT to formazan. Clear zones in the agar indi-
cated the presence of compounds that had inhibited micro-
bial growth [16]. Ciproﬂoxacin, streptomycin, and chloram-
phenicolwereusedaspositivecontrols.Resultsandphotore-
present one of at least 3 independent experiments.
2.7. Bioﬁlm Quantiﬁcation of CaRP. S. epidermidis
ATCC35984 and P. aeruginosa ATCC27853 were used as
modelsofbacterialbioﬁlmformation.Abacterialsuspension
(3×108 CFU/mL)in0.9%NaClwasusedintheassays.Apro-
tocol adapted from Antunes and coworkers [17], using
crystal violet in 96-well ﬂat bottom microtiter plates (Costar
3599, Corning, USA), was applied. Distinct concentrations
(0.125 to 20.0mg/mL) of CaRP in ethanol were tested. Two
hundredµLofeachconcentrationwasasepticallyevaporated
at room temperature during 7h, so that 0.025 to 4.0mg of
C a R Pr e m a i n e di ne a c hw e l l .W e l l sf r o me v a p o r a t e dp u r e
ethanol were used as control since they allowed 100% of
bioﬁlm formation. After ethanol evaporation each well re-
ceived 100µL of bacterial suspension plus 100µL of the
tryptone soya broth (Oxoid Ltd., England) and the plates
were incubated at 37◦C for 24h. The suspension was then re-
moved and the wells washed twice with sterile saline. The
remaining attached bacteria (the bioﬁlm) were heat-ﬁxed
at 60◦C for 1h and stained with crystal violet for 15min
at room temperature. After removing excess stain, the
cell-bound crystal violet was solubilized with DMSO
(Sigma-Aldrich, USA) and its absorbance was measured at
570nm (Spectramax M2e Multimode Microplate Reader,
Molecular Devices, USA). Values higher than 100% (extract-
free control) represent a stimulation of bioﬁlm formation in
comparison to the control. Planktonic bacterial growth was
monitored by calculating the diﬀerence between the OD600
absorbance measured at the end and at the beginning of
the incubation time. Results represent media and standard
deviation of at least 3 independent experiments.
2.8. Scanning Electron Microscopy. Bioﬁlms of S. epidermidis
ATCC35984 and of P. aeruginosa ATCC27853 were grown
in 96-well microtiter plates as described above, with a piece
of Permanox sterile cell culture slide (Nalge, Nunc Inter-
national, USA) added. After 24h of incubation at 37◦C, the
slide samples were withdrawn from the cultures and ﬁxed in
2.5%glutaraldehydefor4h,washedwith100mMcacodylate
buﬀer (pH 7.2), and dehydrated in increasing concentrations
ofacetone,accordingtoTrentinandcoworkers[18].ThePer-
manox slides were dried by the CO2 critical point technique
(CPD 030 Balzers, Liechtenstein), ﬁxed on aluminum stubs,
covered with gold ﬁlm, and examined in a JEOL JSM-6060
scanning electron microscope.
2.9. Fluorescence Microscopy of Bacterial Bioﬁlm Cells. For
ﬂuorescence microscopy, cells were grown in the presence
or absence of CaRP as described in Section 2.7 and suspend-
ed according to Stepanovic and collaborators [19] with slight
adaptations. Brieﬂy, 100µL of cell suspension washed twice
with saline by centrifugation in a microcentrifuge. Cells/bio-
ﬁlm were resuspended in 25µL of saline by vortexing and
submitted to 20min of ultrasound pulses for bioﬁlm disrup-
tion. Then, propidium iodide (PI) was added (1:1 v/v) to a
ﬁnal concentration of 2µM, incubated at room temperature
in the dark for 30min. PI-labeled cells were washed twice
with 400µL of saline and then observed under ﬂuorescence
microscope DMRA2 (Leica) attached with PI ﬁlters. Images
were captured using ×40 objectives under bright ﬁeld as well
as under ﬂuorescent ﬁlters using the IM50 software (Leica).
2.10. LC-UV Microfractionation of CaRP. Micro-fraction-
ation of CaRP was performed according to Queiroz and col-
laborators [20], with slight modiﬁcations. Reversed-phase
HPLC of CaRP fraction was performed on a Shimadzu LC-
20AT Prominence with detector UV-Vis SPD-20A and Col-
lector FRC-10A (Japan). The separations were achieved on a
Gemini C-18 semipreparative column Phenomenex (150 ×
10mm I.D.; 5µm 110 ˚ A) with MeCN-water (5:95 to 95:5;
20h). Sample injection volume was set at 250µL( 1 0 m g ) ,
and ﬂow-rate was 0.2mL/min; the UV traces were measured
at 254 and 347nm. Twenty fractions of 4mL were collected
in plastic tubes for every peak with level >80,000µVa n d
named F1 to F20 (Figure 3). The content of each tube was
concentrated and resuspended in 60µL of MeOH. Fifty µL
of each fraction was used for bioautography and mass spec-
troscopy (MS) analysis.
2.11. ESI-qTOF-MS. Each dried fraction (F6,F 11,F 13,F 18,
and F20) obtained from LC-UV-fractionation was submitted4 Evidence-Based Complementary and Alternative Medicine
to direct infusion in an ESI-q-TOF mass spectrometer
(Waters Q-TOF mass spectrometer). The data was obtained
in mass spectrometer Q-TOF micro from Micromass and
processed using the MassLynx V4.1 software package. High-
purity nitrogen was used as nebulizer and auxiliary gas.
Argonwasusedascollisiongas.ESIcollisionenergy(CE)was
betwen 4 and 45V for negative ion mode. Desolvation tem-
perature was set at 350◦C and source temperature was set
at 120◦C. The desolvation and cone gas ﬂows were 350L/h
and 70L/h, respectively. The sample cone voltage was set at
33V, the extraction voltage was set at 2.5V, and the capillary
voltage was set at 2.5kV. The mass scan range was from 50 to
1500m/z.
2.12.Salmonella/MicrosomeAssay. Mutagenicitywasassayed
by the preincubation procedure. The S9 metabolic activation
mixture (S9 mix) was prepared according to Maron and
Ames [21]. Brieﬂy, 100µL of test bacterial cultures (1-2×109
cells/mL) were incubated at 37◦Cw i t hd i ﬀerent amounts of
CaRP in the presence or absence of S9 mix for 20min, with-
outshaking.Subsequently,2mLofsoftagar(0.6%agar,0.5%
NaCl, 50 µM histidine, 50µM biotin, pH 7.4, 42◦C) were
added to the test tube and poured immediately onto a plate
of minimal agar (1.5% agar, Vogel-Bonner E medium, con-
taining 2% glucose). Aﬂatoxin B1 (1µg/plate) was used as
positive control for all strains in the presence of metabolic
activation (with S9 mix). In the absence of metabolic activa-
tion, 4-nitroquinoline-oxide (4-NQO, 0.5µg/plate) was used
for TA97a, TA98, and TA102 strains, and sodium azide
(1µg/plate) for TA100 and TA1535 strains. Plates were incu-
bated in the dark at 37◦C for 48h before counting the rever-
tant colonies. A test substance was considered mutagenic
when signiﬁcant dose response and ANOVA variance were
observed, and the increase in the mean number of revertants
on test plates was at least twofold higher than that observed
in the negative control plates (or MI ≥ 3 for TA1535 strain).
2.13. Statistical Analysis. Data were calculated as the mean
± standard deviation of at least 3 independent experiments.
ANOVA (Dunnet’s test) was used for the statistical analysis
(P<0.05). For AMES test, the results were analyzed by the
Salmonella Statistic Assay (Environmental Monitoring Sys-
tem Laboratory, EPA-Software Version 2.3, April 1988).
3. Results
3.1. Bioautography. Our ﬁrst goal was to screen CaAE and its
fraction CaRP against bacteria of medical interest, using the
TLC-BAO(Table 1).ResultsdemonstratedthatCaAEdidnot
inhibit any of the tested microorganisms, while CaRP pre-
sented antibacterial activity against S. aureus, S. epidermidis,
B. subtilis and P. aeruginosa.
3.2. Growth Inhibition. Bacterial growth inhibition of S. epi-
dermidis by CaRP at doses from 0.025 to 1mg was dose
dependent,beingsigniﬁcantatdosesof0.5mgorhigher(P<
0.01) when compared to the control (Figure 1(A)). There
was no clear dose dependence in survival when measuring
growth inhibition of P. aeruginosa. Although CaRP fraction
could inhibit the growth at the lowest doses (0.025 to
0.25mg) it showed no eﬀect at 1.0mg (Figure 2(A)).
3.3.BioﬁlmFormationAssay. WetestedtheabilityofCaRPto
prevent bioﬁlm formation of S. epidermidis and P. aeruginosa
(Figures 1(B) and 2(B)) at doses from 0.025 to 1.0mg.
CaRP inhibited bioﬁlm formation of S. epidermidis at doses
f r o m0 . 1t o1 . 0m gw h e nc o m p a r e dt oc o n t r o li nad o s e - d e -
pendent manner (Figure 1(B)). Regarding P. aeruginosa bio-
ﬁlm formation, CaRP could inhibit bioﬁlm formation up to
50% only at the lowest dose (0.025mg), while it had no in-
ﬂuence at all other doses (Figure 2(B)).
3.4. Scanning Electron Microscopy and Fluorescence Micro-
scopy. The eﬀect of CaRP fraction upon S. epidermidis and
P. aeruginosa bioﬁlm morphology was evaluated by scanning
electron microscopy (SEM) (Figures 1(C) and 2(C)). SEM
of CaRP-treated cells conﬁrmed the crystal violet data
(Figure 1(B)), showing that S. epidermidis bioﬁlm formation
occurred at 0.05mg and not at 0.5mg (Figure 1(C)). Cells in
the control were clearly attached to the substratum, forming
bacterial clusters (Figure 1(C)-(a to c)). In treated bioﬁlms,
at 0.05mg, a high number of cell clusters was observed
(Figure 1(C)-(d to f)), while at 0.5mg of CaRP the number
of attached bacterial cells was lower and they appeared only
in small clusters or even as single cells (Figure 1(C)-(g to
i)). Considering P. aeruginosa, images show that the number
of bacterial aggregates decreased when compared with the
control (Figure 2(C)-(atoc));howeveranoverproductionof
EPS matrix was observed at 0.025mg (Figure 2(C)-(d to f)).
Fluorescence microscopy using propidium iodide showed
that almost all treated cells present in the formed bioﬁlm
s t r u c t u r ew e r ed e a d ,e q u a l l yf o rS. epidermidis (Figure 1(D)-
(c to f)) or for P. aeruginosa (Figure 2(D)-(c to d)) when
compared to untreated cells (at inoculation) (Figure 1(D)-
(a and b), and Figure 2(D)-(a and b), resp.). Once again we
could observe that the number of bioﬁlm cells was reduced
by the treatments (mature bioﬁlm) and that control cells
were viable, since they were visible in bright ﬁeld but were
not stained by propidium iodide.
3.5. LC-Microfractionation and Bioautography. Since CaRP
was shown to be active against some bacteria, it was micro-
fractioned by LC in a semipreparative RP-column (Figure 3).
Twenty fractions were obtained and further spotted on TLC
plates and tested for antibacterial activity against the S.
epidermidis, S. aureus, and P. aeruginosa (Figure 3(b) to
Figure 3(d)). From these fractions, ﬁve presented antibac-
terial activity: F6 [yield of 2.3%], F11[52.6%], F13 [3.9%],
F18 [1.5%], and F20 [1.2%]. Fractions F6,F 11,F 18,a n dF 20
inhibited growth of S. aureus (Figure 3(c))a n dS. epider-
midis (Figure 3(d)) whereas fraction F13 was only active
against S. aureus (Figure 3(c)). None of the fractions in the
concentrations (F1 to F20) tested showed activity against P.
aeruginosa (Figure 3(d)). The controls revealed P. aeruginosa
as chloramphenicol resistant (Figure 3(b),C 2 )a n do n l ys e n -
sitive to ciproﬂoxacin and streptomycin (Figure 3(b),C 3a n dEvidence-Based Complementary and Alternative Medicine 5
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Figure 1: (A) Growth of CaRP-treated S. epidermidis ATCC35984, CRT: control; (B) inhibition of bioﬁlm formation of S. epidermidis ∗P<
0.5a n d∗∗P<0.01 related to control (100%); (C) Scanning electron microscopy of S. epidermidis treated with CaRP (a) to (c) control; (d)
to (f) 0.05mg; (g) to (i) 0.5mg of extract; (D) ﬂuorescence microscopy: (a-b) at inoculation; (c-d) 0.05mg; (e-f) 0.5mg of extract mature
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Figure 2: (A) Growth of CaRP-treated P. aeruginosa ATCC27853, CRT: control; (B) Inhibition of bioﬁlm formation of P. aeruginosa ∗P<
0.5a n d∗∗P<0.01 related to control (100%); (C) scanning electron microscopy of P. aeruginosa treated with CaRP (a) to (c) control; (d)
to (f) 0.025mg of extract. ∗P<0.5a n d∗∗P<0.01 related to control (100%); (D) ﬂuorescence microscopy: (a-b) at inoculation; (c-d)
0.025mg of extract, mature bioﬁlm.
C1); S. epidermidis was streptomycin resistant (Figure 3(d),
C1) and sensitive to ciproﬂoxacin and chloramphenicol
while S. aureus was sensitive to streptomycin and chloram-
phenicol (Figure 3(c), C1 and C2).
3.6. Compound Identiﬁcation in CaRP. Kaempferol-O-di-
glucoside, quercetin-O-glucoside, kaempferol-O-glucoside,
kaempferol, rhein, and danthron were identiﬁed from
high-resolution qTOF-MS/MS data as the major active8 Evidence-Based Complementary and Alternative Medicine
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Figure 3: CaRP LC microfractionation and test for bacteriocidic action of spotted fractions via BOD TLC. (a) LC chromatogram revealing
CaRP fractions; bioautography of each fraction against (b) Staphylococcus epidermidis;( c )Pseudomonas aeruginosa; against Staphylococcus
aureus. Controls marked as C1 (Streptomycin 26µg), C2 (Chloramphenicol 24µg), and C3 (Ciproﬂoxacin 6µg).
compounds in fractions F6,F 11,F 18,a n dF 20 obtained from
CaRP after LC microfractionation (Table 3). It was not
possible to identify the compounds present in F13.
3.7. Salmonella/Microsome Mutagenicity Assay. Results on
genotoxicity are shown in Table 2. The CaRP dose range was
determined in a range ﬁnder experiment in strain TA100,
with and without metabolization, and cytotoxicity was not
observed at concentrations up to 5000µg/plate (data not
shown). In the mutagenicity assay the dose range between
1000 and 5000µg/plate was used. The mutagenic eﬀect of
the extract on TA98 strain (detects frameshift mutation in
the DNA target –C–G–C–G–C–G–C–G) in the absence of
metabolic activation indicated that some components of the
extract could eﬀectively interact with DNA. However, the
eﬀect of the extract on the frameshift mutation-detecting
strain TA97a (detects frameshift mutations in –C–C–C–C–
C–C–; +1 cytosine) was not signiﬁcant. Also, no mutagenic-
ity was seen in the strains detecting base pair substitutions
in the absence or presence of metabolic activation: TA1535
and the corresponding isogenic strain TA100 (both detect
base pair substitutions of a leucine-coding GAG triplet to a
proline-coding GGG). Negative results were also observed in
strain TA102, which is sensitive to oxidative and alkylating
mutagens (detects transversions or transitions in TAA DNA
sequences).
4. Discussion
Cassia alata had been mainly used in folk medicine against
constipation and skin diseases [1], and recently biotechno-
logical applications of C. alata extracts have been proposed
for cosmetic industry [1, 22]. The eﬀectiveness of C. alata
aqueous extract against S. aureus, S. pyogenes, E. coli, P.
vulgaris, P. aeruginosa, and C. albicans has been reported
using decoction and MIC [4, 9].
We performed a bioguided-activity fractionation of an
aqueous extract of C. alata (CaAE) employing a cleaner
SPE extraction to obtain the CaRP extract, and a faster and
more economic method, combining TLC and BAO to detect
antimicrobial activity. We also investigated the extract’s in-
ﬂuence on bacterial bioﬁlm formation of S. epidermidis and
P. aeruginosa. Although the crude extract (CaAE) did not
show antimicrobial activity using TLC-BAO (Table 1), CaRP
presented antibacterial activity against S. aureus, S. epider-
midis, B. subtilis, and P. aeruginosa, but was inactive against
E. coli, C. albicans, Salmonella choleraesius, Klebsiella pneu-
monia, and Saccharomyces cerevisiae demonstrating that the
fractionation was successful. The eﬃciency and validity of
TLC-BAO method could be veriﬁed with positive controls of
antibiotics (Table 1).
Pathogenicbioﬁlm-formingmicroorganismsarefocusof
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of chronic infectious diseases and medical device-related
infections [12]. This indicates the need to search for new
antimicrobial resources, including plants used in traditional
medicinethatmaycontainagreatvarietyofcompoundswith
therapeutic properties [18].
Inhibition of bacterial growth and of bioﬁlm formation
by CaRP was dose dependent (Figure 1(A), 1(B) and 1(C))
in S. epidermidis. SEM images showed that CaRP prevented
signiﬁcantly formation of bioﬁlm at the highest dose used
(Figure 1(B) and 1(C)). Cells in the control were clearly
cemented to the substratum and formed nascent cell cluster
(Figure 1(C)-(a to c)) while the amount of cells in the clus-
ters, embedded in the EPS matrix was diminished after
CaRP treatment (Figure 1(C)-(d to i)). It seems that bac-
terial growth was inhibited before the cells were able to
promote adhesion on the surface (Figures 1(A) and 1(C)). In
the same way, it was recently shown via SEM that S. epider-
midis exhibited diﬀerent morphology after treatment with
vancomycin, that is, there was a diﬀerential impact on S.
epidermidis morphology in the center and periphery of bio-
ﬁlm upon treatment, suggesting a spatial distribution of
vancomycin-induced damage in S. epidermidis bioﬁlm [23].
Regarding P. aeruginosa t h e r ew a sn od o s ed e pe n d e n c ee ﬀect,
neither in growth inhibition (Figure 2(A)) nor in antibioﬁlm
activity according to the results of the OD600 measurements
and CV method, respectively (Figure 2(B)). Interestingly, the
bacterial growth was only inhibited signiﬁcantly at low dose
of CaRP (Figure 2(A)) and CaRP inhibited 43% of bio-
ﬁlm formation only at 0.025mg (Figure 2(B)). Although the
number of bacterial aggregates decreased, an overproduc-
tion of EPS matrix was observed (Figure 2(C)-(d to f)).
The matrix production in P. aeruginosa is regulated by the
quorum sensing (QS) system. QS is a bacterial cell-cell com-
munication which associates speciﬁc genes’ transcription
with cell density [24]. Since matrix production is modulated
by CaRP it is therefore plausible that some kind of aber-
rant regulation of QS occurs in this process. Analyzing
the data together, it seems that CaRP probably triggers the
modulation of EPS production in P. aeruginosa and, there-
fore, the cell organization (Figure 2(C)-(b and e)). The re-
covery of the ability to form bioﬁlm by P. aeruginosa at high-
er doses of CaRP might be related to some fraction compo-
nent(s), which compensate the observed antibioﬁlm activity
at low doses. Results obtained by ﬂuorescence microscopy
corroborate with the growth inhibition data, proving that
the antibioﬁlm CaRP activity is closely related to growth
inhibition, as almost all cells present in the bioﬁlm structure
are dead (Figures 1(D) and 2(D)).
Since CaRP demonstrated diﬀerent antibacterial eﬀects,
we expected that it might contain distinct active compounds.
Microfractionation and TLC (Figure 3) showed 4 subfrac-
tions active against S. epidermidis b u tn o n eo ft h e mw a s
active against P. aeruginosa (Figures 3(b) and 3(c)). This
may be explained by the small amount of substance in each
fraction that did not any longer allow inhibitory activity on
a bacterium with higher resistance. The alternative explana-
tion for the observed antibacterial activity of CaRP could
be a synergistic interaction of at least 2 compounds of this
fraction. In order to establish a general antibacterial activity
of some fractions we used the same method against S. aureus
(Figure 3(d)). Indeed, the same 4 fractions (F6,F 11,F 18,a n d
F20)p l u so n e( F 13) promoted growth inhibition in this bac-
terium.
In order to identify the secondary metabolites of C. alata
that could be responsible for cytotoxicity and bioﬁlm inhibi-
tion, we performed high-resolution mass spectrometry of
the obtained subfractions from CaRP. It was possible to
identify four ﬂavonoids (present in F6,F 11,a n dF 18)a n d
two anthraquinones (present in F20)( Table 3). Flavon-
oids have been described as health-promoting, disease-pre-
venting dietary supplements, and to have activity as can-
cer-preventive agents. Additionally, they are considered ex-
tremely safe and have low toxicity, making them excellent
candidates for chemopreventive agents [25]. Flavonoids,
such as kaempferol and quercetin are known to have a wide
range of pharmacological activities, including antioxidant,
anti-inﬂammatory, antimicrobial, anticancer, cardioprotec-
tive, neuroprotective, antidiabetic, antiosteoporotic, estro-
genic/antiestrogenic, anxiolytic, analgesic, and antiallergic
activities [26]. However, it still remains to be determined
whether these properties, for example, those of quercetin,
areaﬀectedindependentlyorshareacommonmechanismof
action [27]. Natural compounds are reported to inhibit bio-
ﬁlm formation by various mechanisms without aﬀecting the
m i c r o b i a lg r o w t hr a t e[ 28, 29]. It is possible that the vari-
ous known ﬂavonoids may have diﬀerential modes of action
in inhibiting formation of bioﬁlm. Indeed, both kaemp-
ferol and quercetin have recently been shown to be eﬀective
antagonists of cell-cell signaling and to suppress bioﬁlm
formation in Vibrio harveyi and E. coli O157:H7 cultures
(at doses ranging from 6–100µg/mL), indicating a potential
modulation by thesecompounds of bacterialcelltocellcom-
munication. Similarly, both molecules in our study could
act synergistically in their contribution to inhibit bioﬁlm
formation of S. epidermidis and P. aeruginosa (Figures 1(C)
and 2(C)).
Whileﬂavonoidsareusuallyconsideredbeneﬁcialforhu-
man health [25], anthraquinones such as danthron (1,8-di-
hydroxyanthraquinone) have been described as possible hu-
man carcinogens [30] and to induce DNA damage and
apoptosis in various mammalian cells at a dose range of 25–
100µg/mL [31]. They still have not yet been described as
responsible for bioﬁlm inhibition. Identiﬁcation and quan-
tiﬁcation of anthraquinones in biological matrices have
been widely described and this improved considerably our
understanding of their mechanism of action. However, their
biological targets have not yet been totally deﬁned [32].
Anthraquinones are chemical derivatives of quinones, which
are believed to react with sulfhydryl (–SH) groups, a critical
reaction since blocking of –SH groups of enzymes may in-
hibit their activity. Oxidative reaction with –SH groups will
also change the cellular redox potential [33]. Inhibition of
the catalytic activity of topoisomerase II has been shown to
contribute to anthraquinone-induced genotoxicity and mu-
tagenicity [34].
One possible mechanism of action of danthron is that it
may cause DNA damage particularly at guanines in the pre-
sence of Cu(II), cytochrome P450 reductase, and the12 Evidence-Based Complementary and Alternative Medicine
NADPH-generating system, which led to the conclusion that
oxidative DNA damage by danthron may be relevant for the
initiation of cancer [35].
WehaveobservedthatgrowthinhibitionofS.epidermidis
by CaRP was dose dependent (Figure 1(A)), while that of P.
aeruginosa (inhibition only at lowest doses) was not. Since
it is known that inhibition of bioﬁlm formation may occur
without aﬀecting growth rate [28, 29], this could be in-
terpreted that anthraquinones rather than ﬂavonoids may
negatively interact with DNA or enzymes, and that bioﬁlm
inhibition may be, therefore, a consequence of both biologi-
cally toxic events.
Regarding the fact that folk medicine uses whole plant
extracts as remedy we also assayed the whole extract (CaRP)
for its genotoxicity. Our data on mutagenicity show CaRP
to be slightly mutagenic, but only in strain TA98 (Table 2).
Recently, danthron has been shown to be mutagenic in S.
typhimurium strain TA102 in presence of exogenous meta-
bolic activation (S9 mix) and weakly mutagenic in TA1537
withorwithoutmetabolicactivation[31,36]whilerheinwas
found to be mutagenic in tester strain TA102 [37]. A review
of the data related to the safety of quercetin reports lack of
evidence of in vivo toxicity, including lack of genotoxic/car-
cinogenic properties [27], while data regarding the safety
of kaempferol is conﬂicting: some studies show kaempferol
to induce antimutagenic activity [26], while other reports
haverevealedthatthisﬂavonoidmayinducegenotoxiceﬀects
[26]. With respect of our data of weak genotoxicity of CaRP
in the Salmonella/microsome assay, we may speculate that
anthraquinones rather than ﬂavonoids are the causal agents.
5. Conclusions
As important conclusions of our work we may summarize
our conclusion as follows:
(i) This is the ﬁrst study showing the ability of C. alata
metabolites upon two important bioﬁlm-forming
pathogens.
(ii) The antibioﬁlm CaRP activity is closely related to
growth inhibition, as almost all cells present in the
treated bioﬁlm structure are dead.
(iii) This is the ﬁrst study presenting the genotoxicity eva-
luation for this very common and much-used medic-
inal plant.
(iv) Our extract characterization identiﬁed the major
components of CaRP as 4 ﬂavonoids and 2 anthra-
quinones.
(v) C. alata might be a source of compounds that inhibit
bioﬁlm formation.
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